IMFINZI Specific-Clinical Experience Investigation in patients with NSCLC after definitive chemoradiation therapy

Trial Identifier: D4194C00003
Sponsor: AstraZeneca
NCTID:: NCT03643484
Start Date: October 2018
Primary Completion Date: June 2021
Condition: Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Japan Aichi, Japan, D4194C00003
Japan Akita, Japan, D4194C00003
Japan Aomori, Japan, D4194C00003
Japan Chiba, Japan, D4194C00003
Japan Ehime, Japan, D4194C00003
Japan Fukui, Japan, D4194C00003
Japan Fukuoka, Japan, D4194C00003
Japan Fukushima, Japan, D4194C00003
Japan Gifu, Japan, D4194C00003
Japan Gunma, Japan, D4194C00003
Japan Hiroshima, Japan, D4194C00003
Japan Hokkaido, Japan, D4194C00003
Japan Hyogo, Japan, D4194C00003
Japan Ibaraki, Japan, D4194C00003
Japan Ishikawa, Japan, D4194C00003
Japan Ishikawa, Japan
Japan Iwate, Japan, D4194C00003
Japan Kagawa, Japan, D4194C00003
Japan Kagoshima, Japan, D4194C00003
Japan Kanagawa, Japan, D4194C00003
Japan Kochi, Japan, D4194C00003
Japan Kumamoto, Japan, D4194C00003
Japan Kyoto, Japan, D4194C00003
Japan Mie, Japan, D4194C00003
Japan Miyagi, Japan, D4194C00003
Japan Miyazaki, Japan, D4194C00003
Japan Nagano, Japan, D4194C00003
Japan Nagasaki, Japan, D4194C00003
Japan Nara, Japan, D4194C00003
Japan Niigata, Japan, D4194C00003
Japan Okayama, Japan, D4194C00003
Japan Okinawa, Japan, D4194C00003
Japan Osaka, Japan, D4194C00003
Japan Saga, Japan, D4194C00003
Japan Saitama, Japan, D4194C00003
Japan Shiga, Japan, D4194C00003
Japan Shizuoka, Japan, D4194C00003
Japan Tochigi, Japan, D4194C00003
Japan Tokyo, Japan, D4194C00003
Japan Tottori, Japan, D4194C00003
Japan Toyama, Japan, D4194C00003
Japan Wakayama, Japan, D4194C00003
Japan Yamagata, Japan, D4194C00003
Japan Yamaguchi, Japan, D4194C00003
Japan Yamanashi, Japan, D4194C00003